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ABSTRACT
The aim of this work was to prepare microcapsules containing naproxen that
could be used in the preparation of oral controlled released forms. The work consisted on
the preparation of microcapsules by the solvent evaporation method. Different batches
were prepared, in the first step, using different polymers (Eudragit RLPO and Eudragit
RSPM) or mixtures of these polymers (Eudragit RLPO/Eudragit RSPM 1/3, 2/2 and 3/1)
and, in second step, using Eudragit RLPO and 5% of Cutina (HR, KD 16 and MD). The
film-forming properties of polymers and different types of Cutina were examined and
the physicochemical factors that influence drug release from the films were studied. The
evaluation of the release rate of these preparations was performed in pH 7.4 phosphate
buffer solution, during 12 hours. The release studies of naproxen preparations demon-
strated differences in the drug release properties depending on the polymer or the content
of the polymer in the mixtures and also on the type of Cutina.
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RESUMEN
Diseño y desarrollo de microcapsulas orales de liberación controlada de naproxeno
El objetivo de este trabajo fue preparar micro cápsulas de naproxeno que pue-
dan ser usadas en la preparación de formas orales de libertación controlada.
Las microcápsulas fueron preparadas por el método de la evaporación del sol-
vente. Diferentes lotes fueron preparados, primero usando diferentes polimeros (Eudragit
RLPO y Eudragit RSPM) o mezclas de polímeros (Eudragit RLPO/Eudragit RSPM
1/3,2/2 y 3/1) y después usando Eudragit RLPO y 5% de Cutina (HR, KD 16 y MD).
Las propiedades de formación de películas por los polímeros y las diferentes
cutinas fueron estudiadas bien como los fatores fisico-quimicos que influencian la
libertación del naproxeno por las películas.
El perfil de libertación del naproxeno en las diferentes formulaciones preparadas, fue
estudiado en tampón de fosfatos a pH 7.4, durante 12 h.
Los estudios de libertación del naproxeno en las diferentes formulaciones de-
mostraran diferencias en las propiedades de libertación del naproxeno, dependiendo del
polimero utilizado, del contenido de las mezclas y del tipo de cutina usados.
Palabras-clave: Micro cápsulas.ʊ Naproxeno.ʊ Libertación oral controlada.
INTRODUCTION
Several drugs, have been microencapsulated to reduce gastric and 
other gastrointestinal tract irritations including indomethacin (1), aspirin 
(2) and biphenylylacetic acid (3). In addition, most of the orally adminis-
tered acidic non-steroidal anti-inflammatory drugs are irritant to the 
gastric mucosa if taken for a prolonged period of time (4). 
Naproxen, a non-steroidal anti-inflammatory agent with anti-
inflammatory, analgesic and antipyretic properties, practically insoluble
in water and freely soluble in alcohol, was selected since the drug exhibits 
all the required pharmacokinetic and physicochemical properties, which 
make it a good candidate to be incorporated in a controlled release dosage
form (5). 
Polyacrylate-polymethacrylate copolymers (Eudragits) are widely 
used as tablet adjuvants and coating polymers. These polyacrylate 
polymers were also used for drug microencapsulation as microcapsule
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wall materials. In fact, acrylate polymers and their derivates, collectively
known as Eudragit polymers, origin films with excellent strength and 
good flexibility and aesthetics (6-9).
The two acrylic resins evaluated in this study included Eudragit 
RLPO and RSPM. The RL and RS acrylic resins are copolymers synthe-
sised from acrylic and methacrylic acid esters with a low content of
quaternary ammonium groups as chloride salts. The swelling capacity and 
the permeability to water and dissolved drugs were defined, which is pH 
independent. The RL resin is freely permeable whereas the RS resin is 
slightly permeable to water.
The three different types of Cutina, used as plasticizers, evaluated
in this study included Cutina HR (Castor oil, hardened), KD 16 (self-
emulsifying mixture of mono- and diglycerides of higher saturated fatty 
acids and potassium stearate) and MD (mixture of mono- and diglycerides 
of palmitic and stearic acid).
The aim of this work was to prepare microcapsules containing
naproxen that could be used in the preparation of oral controlled release
forms. The work consisted on the preparation of microcapsules by the
solvent evaporation process. Different batches were prepared using two 
polymers or mixtures of polymers and adding three types of Cutina. The 
film-forming properties of polymers were examined and the physico-
chemical factors that influence drug release from the films were studied.
EXPERIMENTAL
Materials
Naproxen was kindly supplied by Janssen Cilag and Eudragit RS 
PM and RL PO by Rohm Pharma GmbH. The different types of Cutina 
were purchased from Henkel. All other materials and solvents were of
analytical reagent grade.
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Preparation of naproxen microcapsules
After preliminary studies, the following optimal experimental
conditions were chosen for the preparation of naproxen microcapsules on 
a dissolution apparatus (paddle method). Liquid paraffin (300 ml) was
placed on a vessel at 37ºC. A solution containing 0.75 g of naproxen, 2.5
g of polymer or mixtures of polymers, 0.0625 g of Cutina and 0.125 g of 
magnesium stearate in 60 ml of acetone was added to paraffin through a
separating funnel. The mixture was stirred at 200 rpm. The resulting
emulsion was agitated at 37ºC for 4 h and during this time acetone was
evaporated. The resultant microcapsules were isolated by filtration, 
washed with cyclohexan and dried at room temperature for 12 h. 
The empty microcapsules were prepared using identical experi-
mental conditions but in the absence of naproxen. 
The prepared formulations are shown in Table 1. 
Table 1. Naproxen microcapsules formulations prepared by the solvent evaporation
process.
Formulations
Components A B C D E F G H
Naproxen 0.750 0.750 0.750 0.750 0.750 0.750 0.750 0.750
Eudragit RS PM 2.500 1.875 1.250 0.625 - - - -
Eudragit RL PO - 0.625 1.250 1.875 2.500 2.500 2.500 2.500
Cutina (0.0625
g)
- - - - - HR KD 16 MD
Magnesium
Stearate
0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125
Naproxen content 
Naproxen microcapsules were weighed, dissolved in chloroform
and filtered. Naproxen was assayed by UV analysis using a calibration
curve at 331 nm.
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Microscopy studies and particle size distribution 
Optical microscopy was used to evaluate the drug incorporation 
and the surface shape of the microcapsules. Particle size was determined
by optical microscopy. Samples of microcapsules (200) were dispersed on 
a slide and its diameter was evaluated. The microcapsules particle size 
distribution was also evaluated by sieving. 
Differential scanning calorimetry 
Differential thermal analysis (heating cycles of 25ºC-280ºC) of 
pure naproxen, empty Eudragit and empty Eudragit/Cutina microcapsules,
Eudragit and Eudragit/Cutina microcapsules containing naproxen, 
mechanical mixtures of naproxen, Eudragit, Cutina and magnesium
stearate was carried out with a computer-interfaced Shimadzu differential
scanning calorimeter, Model DSC-50. The samples (2.6-2.8 mg), which 
were stored in a desicator prior to the analysis, were sealed in aluminum
pans. The scanning rate throughout the investigation was 10ºC/min. All 
tests were run in triplicate and the DSC cells were purged with nitrogen at
20.0 ml/min.
Release studies
The dissolution test was carried out using the European Pharma-
copoeia apparatus at a basket speed of 100 rpm. The dissolution medium
was 500 ml of a pH 7.4 phosphate buffer solution, maintained at 37ºC r
0.5ºC. At appropriate time intervals (30, 60, 120, 240, 360, 480 and 480 
min), 25 ml of each was withdrawn and equal volume of medium was
added to maintain a constant volume. Samples were filtered, diluted and
analysed by UV spectophotometry at 331 nm on a Hitachi 2000 spectro-
photometer.
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RESULTS AND DISCUSSION 
The microcapsules loading of naproxen was theoretically calcu-
lated and the intended value was 22.2%. The naproxen content of the
microcapsules varied from 14.8% to 15.3 % for microcapsules containing 
polymer. However, when the microcapsules included plasticizers the 
naproxen content was between 15.9% and 16.8%, as it can be seen in 
Table 2. 
Table 2. Naproxen loading of the microcapsules.
Formulations Loading (%)
A 14.8
B 15.2
C 14.8
D 15.3
E 14.9
F 16.8
G 16.1
H 15.9
140
VOL. 69 (1), MICROCÁPSULAS ORALES DE LIBERACIÓN CONTROLADA DE NAPROXENO
Figure 1. DSC scans of pure naproxen, Eudragit RL PO microcapsules containing
naproxen, Cutina MD and magnesium stearate (A), pure naproxen, mechanicals
mixtures of naproxen and Eudragit RL PO (B) at heating rate of 10ºC/min.
A
B
The differential scanning calorimetry (DSC) analysis (Figure 1) 
showed that there were no thermal events during the examination of 
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empty microcapsules. However, in the case of the melting phase transi-
tion of pure naproxen, a sharp endotherm was observed at approximately
155ºC corresponding exactly to the melting point of naproxen. To shed 
further light on the nature of Eudragit-naproxen interaction, different 
mechanical mixtures were prepared and examined by DSC. When the 
naproxen content in the mixtures was decreased, the peak at 155ºC
decreased and became negligible at approximately 50% naproxen. When
the microcapsules naproxen content was about 15%, the thermal behav-
iour of naproxen microcapsules was similar to the observed with pure
Eudragit, as the peak at 155ºC became negligible.
The microscopic analysis of microcapsules containing naproxen 
revealed its spherical shape. As it can be observed in Figure 2, the
morphological examination of the microcapsules, performed at the 
beginning and at different times of the release study by optical micros-
copy, showed that the products were homogeneous with corrugated 
surfaces and pores. Higher magnification revealed surface shrinkage.
After dissolution test the microcapsules did not change in shape, which 
suggests that naproxen diffused out through the minor pores and channels. 
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The results obtained in the sieving evaluation of the microcapsules
particle size distribution are shown in Table 3. It is possible to verify that 
all batches presented a similar and regular size distribution. 
B
Figure 2. Scanning optical micrograph of naproxen microcapsules before (A) and
after (B) dissolution test.
A
Table 3. Microcapsules size distribution (%).
Characteristics Formulations
(Pm) A B C D E F G H
1000-1250 36 31 30 28 22 25 31 41
710-1000 50 49 45 50 53 15 36 16
520-710 14 20 21 18 21 21 27 28
250 - 520 - - 4 3 2 32 5 12
< 250 - - - 1 2 7 1 3
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The naproxen release profiles from the eight different microcap-
sules formulations are shown in Figure 3 and 4. The drug release profiles 
were plotted against time and some mathematical models (Zero-order,
First-order and Higuchi Law) were applied. 
Figure 3. Release profiles of A (RS PM), B (RL PO), C (RS PM/RL PO 
75/25), D (RS PM/RL PO 50/50) and E (RS PM/RL PO 25/75) formulations.
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Figure 4. Release profiles of E (RL PO), F (RL PO/Cutina HR), G (RL
PO/Cutina KD 16) and D (RL PO/Cutina MD) formulations.
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The results obtained in the release studies are shown in Table 4. It 
is possible to observe that the release kinetics from the microcapsules
containing naproxen followed the Higuchi equation up to 79.9% of the
cumulative drug release.
As expected, a higher release rate was obtained when the Eudragit 
RS PM content decreased or when Eudragit RL PO increased. When 0%, 
25%, 50%, 75% and 100% of Eudragit RS PM was incorporated into the
formulations, the amount of released naproxen decreased to 79.9%, 
66.3%, 42.2%, 19.9% and 16.5% after 12 h, respectively. 
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Table 4. Values of kinetic constant (k), y-intercept (b) and correlation coefficient (R2)
following linear regression of release studies.
Formulations
A B C D E D E F
Zero-
order
k
b
R2
0.913
5.830
0.969
5.795
16.609
0.956
1.076
7.735
0.979
2.790
10.930
0.965
4.761
13.740
0.950
6.085
17.402
0.947
6.329
18.966
0.955
6.670
24.418
0.950
First-
order
k
b
R2
0.089
1.828
0.883
0.144
2.930
0.823
0.083
2.101
0.920
0.121
2.488
0.855
0.146
2.722
0.796
0.147
2.959
0.807
0.142
3.050
0.818
0.129
3.278
0.823
Higuchi
k
b
R2
3.814
2.644
0.975
24.654
- 4.484
0.997
4.519
3.934
0.994
11.826
0.864
0.998
20.272
- 3.619
0.992
26.018
4.999
0.997
26.968
-4.154
0.999
28.487
-0.075
0.998
According to the release studies results obtained, Eudragit RSPM
microcapsules showed a naproxen release lower than Eudragit RLPO 
microcapsules. These results suggest that the nature of the polymer has a 
significant effect on the release rate of naproxen when incorporated into
these microcapsules formulations. Therefore, the preliminary results
suggest that in the experimental conditions and with the polymers used in
the present study, it is possible to prepare microcapsules for an oral 
controlled release form of naproxen.
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